Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,440 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Novel Anti-TM4SF1 Antibody-Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature.
Visintin A, Knowlton K, Tyminski E, Lin CI, Zheng X, Marquette K, Jain S, Tchistiakova L, Li D, O'Donnell CJ, Maderna A, Cao X, Dunn R, Snyder WB, Abraham AK, Leal M, Shetty S, Barry A, Zawel L, Coyle AJ, Dvorak HF, Jaminet SC. Visintin A, et al. Among authors: leal m. Mol Cancer Ther. 2015 Aug;14(8):1868-76. doi: 10.1158/1535-7163.MCT-15-0188. Epub 2015 Jun 18. Mol Cancer Ther. 2015. PMID: 26089370
Anti-Extra Domain B Splice Variant of Fibronectin Antibody-Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade.
Hooper AT, Marquette K, Chang CB, Golas J, Jain S, Lam MH, Guffroy M, Leal M, Falahatpisheh H, Mathur D, Chen T, Kelleher K, Khandke K, Muszynska E, Loganzo F, Rosfjord E, Lucas J, Kan Z, Subramanyam C, O'Donnell C, Neri D, Gerber HP, May C, Sapra P. Hooper AT, et al. Among authors: leal m. Mol Cancer Ther. 2022 Sep 6;21(9):1462-1472. doi: 10.1158/1535-7163.MCT-22-0099. Mol Cancer Ther. 2022. PMID: 35793468 Free PMC article.
Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells.
Sapra P, Damelin M, Dijoseph J, Marquette K, Geles KG, Golas J, Dougher M, Narayanan B, Giannakou A, Khandke K, Dushin R, Ernstoff E, Lucas J, Leal M, Hu G, O'Donnell CJ, Tchistiakova L, Abraham RT, Gerber HP. Sapra P, et al. Among authors: leal m. Mol Cancer Ther. 2013 Jan;12(1):38-47. doi: 10.1158/1535-7163.MCT-12-0603. Epub 2012 Dec 5. Mol Cancer Ther. 2013. PMID: 23223830
Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia.
Han YC, Kahler J, Piché-Nicholas N, Hu W, Thibault S, Jiang F, Leal M, Katragadda M, Maderna A, Dushin R, Prashad N, Charati MB, Clark T, Tumey LN, Tan X, Giannakou A, Rosfjord E, Gerber HP, Tchistiakova L, Loganzo F, O'Donnell CJ, Sapra P. Han YC, et al. Among authors: leal m. Clin Cancer Res. 2021 Jan 15;27(2):622-631. doi: 10.1158/1078-0432.CCR-20-2149. Epub 2020 Nov 4. Clin Cancer Res. 2021. PMID: 33148666
1,440 results